Charles River Laboratories International, Inc. (FRA:RV6)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.58B +82.5% |
| Revenue (ttm) | 3.51B -0.7% |
| Net Income | -209.08M |
| EPS | -4.28 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 22.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109 |
| Open | 245.10 |
| Previous Close | 238.60 |
| Day's Range | 244.00 - 245.10 |
| 52-Week Range | 124.25 - 255.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About FRA:RV6
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]
News
Charles River price target raised to $330 from $250 at Argus
Argus raised the firm’s price target on Charles River (CRL) to $330 from $250 and keeps a Buy rating on the shares. The firm is citing the company’s stronger EPS…
Charles River introduces rapid cell banking programs to reduce timelines
Charles River (CRL) Laboratories International has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy develo...
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release ti...
Charles River Laboratories International Transcript: 2026 Global Healthcare Conference
Leadership transition has been smooth, with a renewed focus on modernization and client-centric growth. Strong financial performance is supported by robust bookings and backlog recovery, while operational improvements and supply chain investments position the company for continued margin expansion and growth.
Charles River Laboratories International Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership transition has been smooth, with strategy validated and demand improving across key segments. Portfolio optimization and acquisitions have positioned the business for growth, while AI and complex modalities are expected to drive future demand. Investor Day will outline grounded, execution-based targets.
Charles River price target raised to $320 from $300 at Evercore ISI
Evercore ISI raised the firm’s price target on Charles River (CRL) to $320 from $300 and keeps an Outperform rating on the shares ahead of the company’s investor day event.
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.
Charles River implements Endosafe Cartridge Technology Automated Manufacturing
Charles River (CRL) Laboratories implemented its Endosafe Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands...
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Su...
Charles River, Medigen Vaccine to advance new vaccine development programs
Charles River (CRL) Laboratories International and Medigen Vaccine Biologics collaborate on the characterization and validation of the virus seed bank for MVC’s next-generation multivalent enterovirus...
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validati...
How an Insider CEO Is Taking a Fresh Look at Charles River
Even after 35 years and by her count 16 or 17 different jobs across every division at Charles River Laboratories, Birgit Girshick still made visiting the company's far-flung outposts one of her first ...
Charles River price target raised to $300 from $235 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Charles River (CRL) to $300 from $235 and keeps a Buy rating on the shares. The firm updated its…
Charles River price target raised to $264 from $230 at Mizuho
Mizuho raised the firm’s price target on Charles River (CRL) to $264 from $230 and keeps a Neutral rating on the shares.
Charles River price target raised to $300 from $260 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Charles River (CRL) to $300 from $260 and keeps an Overweight rating on the shares.
Charles River price target raised to $291 from $255 at Baird
Baird raised the firm’s price target on Charles River (CRL) to $291 from $255 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Charles River price target raised to $300 from $260 at Deutsche Bank
Deutsche Bank analyst Justin Bowers raised the firm’s price target on Charles River (CRL) to $300 from $260 and keeps a Buy rating on the shares.
Charles River price target raised to $282 from $215 at RBC Capital
RBC Capital raised the firm’s price target on Charles River (CRL) to $282 from $215 and keeps an Outperform rating on the shares.
JPMorgan upgrades Charles River to Overweight following strong Q2
JPMorgan upgraded Charles River (CRL) to Overweight from Neutral with a price target of $310, up from $180. The company delivered strong Q2 results while raising 2026 guidance on the…
Charles River upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Charles River (CRL) to Overweight from Neutral with a price target of $310, up from $180.
Charles River price target raised to $300 from $220 at Barclays
Barclays raised the firm’s price target on Charles River (CRL) to $300 from $220 and keeps an Overweight rating on the shares.
Charles River price target raised to $300 from $260 at Evercore ISI
Evercore ISI raised the firm’s price target on Charles River (CRL) to $300 from $260 and keeps an Outperform rating on the shares. The company’s first quarter of organic revenue…
Charles River Laboratories International Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations, with organic revenue growth, margin expansion, and strong DSA bookings. Full-year guidance was raised for revenue, EPS, and free cash flow, supported by portfolio refinement and robust biopharma demand.
Charles River Laboratories International Earnings release: Q2 2026
Charles River Laboratories International released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.